NewsOct 31, 2018Soricimed Publishes New Research Validating TRPV6 as a Therapeutic Target for Ovarian Cancer
NewsMar 19, 2018Soricimed Announces the Appointment of Dr. Marc Rubin and Mr. Vaughn Embro-Pantalony to Board of Directors
/img/newsandevents/San_Fran_thumb.jpgEventsSep 20, 2017World ADC San Francisco 2017, San Francisco, CA
/img/newsandevents/San_Diego_thumb.jpgEventsJun 4, 20172017 BIO International Convention, San Diego, CA
NewsSep 27, 2016Soricimed’s SOR-C13 Granted Orphan Drug Designation for Pancreatic Cancer by the U.S. FDA
/img/newsandevents/San_Fran_thumb.jpgEventsJun 9, 20162016 BIO International Convention, San Francisco, CA
/img/newsandevents/San_Diego_thumb.jpgEventsMay 12, 2016ACCR (American Academy for Cancer Research) Pancreatic Cancer: Advances in Science and Clinical Care, Orlando, Florida
/img/newsandevents/New_Orleans_thumb.jpgEventsApr 16, 2016AACR (American Academy for Cancer Research), New Orleans, Louisiana
NewsApr 12, 2016Soricimed Announces Presentations at the Upcoming American Association of Cancer Research (AACR) Annual Meeting
NewsMar 8, 2016Soricimed Granted Orphan-Drug Designation from the U.S. FDA for Treatment of Ovarian Cancer
NewsFeb 23, 2016Soricimed Announces Positive Top-Line Results in Phase 1 Trial of First-in-Class Peptide SOR-C13 in Subjects with Advanced Solid Tumour Cancers
NewsMay 6, 2015Targeting TRPV6 with Soricimed’s Novel SOR-C13 Inhibits Tumour Growth in Breast and Ovarian Cancer Models
NewsMay 6, 2015Soricimed’s Findings Support TRPV6 as a Novel and Significant Biomarker for Ovarian Cancer-Targeted Therapies and Diagnostics
NewsNov 4, 2013Toxicology Study of Soricimed’s Anti-Cancer Agent Presented at ACT Conference in San Antonio
NewsOct 15, 2013Soricimed Shows Promise In Treating Breast and Ovarian Cancer With Peptide-Paclitaxel Conjugate
/img/newsandevents/San_Fran_thumb.jpgEventsSep 20, 2013World ADC San Francisco 2013, San Francisco, CA
NewsJul 16, 2013Soricimed Biopharma Inc. Appoints Tom Reeves to Board of Directors and Welcomes Mario Thomas, PhD, to the Executive Team
NewsMay 28, 2013Jack Stewart, Chairman and Chief Scientific Officer of Soricimed, speaks on proof-of-concept study results at annual cancer research workshop.
NewsMay 23, 2013Soricimed Biopharma Inc. Announces U.S. Trial Site for Phase I Clinical Trial of New Cancer Drug, SOR-C13
NewsMar 19, 2013Soricimed’s Peptides Used to Detect Ovarian and Prostate Cancer - Proof of Concept Published in Peer-Reviewed Publication
